PTN News

  • Safety of Sildenafil in Premature Infants Study to Open Third Cohort Soon April 6, 2022
    The Pediatric Trials Network (PTN) plans to open the third and final cohort (or group of study participants), in the Safety of Sildenafil in Premature Infants study in the near future. A total of 80 premature infants have been enrolled in the study so far, into the first and second study cohorts. These first and ...
  • 2020/2021 PTN Annual Report is Available March 24, 2022
    The 2020/2021 PTN Annual Report is now available. Click here to access. A note from the PTN Steering Committee Chairs: The COVID-19 pandemic has continued to challenge us in unparalleled ways and we are grateful for the commitment the Pediatric Trials Network (PTN) has exemplified in learning more about COVID as related to our youngest of patients. ...
  • Clindamycin Label Updated to Include Dosing Information for Premature and Term Infants February 15, 2022
    A Pediatric Trials Network (PTN) pharmacokinetic (PK) study recently contributed to a medication label change for the drug clindamycin. This research effort, which involved analysis data from 4 studies (Pharmacokinetics of Antistaphylococcal Antibiotics in Infants, Pharmacokinetics of Understudied Drugs Administered to Children, and Safety and Pharmacokinetics of Multiple-Dose Intravenous and Oral Clindamycin, and Antibiotic Safety in ...
  • PTN Research Informs Diazepam Label Change February 4, 2022
    A PTN pharmacokinetic (PK) study recently contributed to a medication label change for the drug diazepam. This research effort, Population Pharmacokinetics and Exploratory Exposure-Response Relationships of Diazepam in Children Treated for Status Epilepticus, contributed pharmacokinetic and dosing data for the intravenous (IV) administration of diazepam. This drug is a benzodiazepine clinically indicated in children for the management ...
  • ANA Study Updates Protocol to Include New Medications January 12, 2022
    The PTN’s Anesthesia and Analgesics in Children (ANA) study has updated its study protocol to include new medications to be studied in pediatric populations. These new medications being studied, known as drugs of interest (DOI), include morphine, oxycodone, and ketamine. Although often prescribed by providers for anesthetic and analgesic (or pain relief) reasons, the safety, ...
  • LAPS Trial Meets Study and Sub-Study Milestones December 15, 2021
    The PTN Long-term Antipsychotic Pediatric Safety (LAPS) Trial, which aims to assess the long-term health of risperidone and aripiprazole in children, has enrolled more than 500 children in the main study. Risperidone and aripiprazole have been shown to be effective for the treatment of conditions such as schizophrenia and bipolar disorder in adults and children. ...
  • PTN Receives Funding to Study Device Used to Treat Overactive Bladder November 5, 2021
    The Pediatric Trials Network (PTN) is thrilled to announce the Network has received funding from the Best Pharmaceuticals for Children Act (BPCA) to study a device to treat Overactive Bladder (OAB) in pediatric patients. The project is planned as a collaboration with industry partner Laborie Medical Technologies Corp, who will provide devices for the study. Overactive ...
  • PTN Makes COVID Data Publically Available As Part of CARING Collaboration October 28, 2021
    The PTN Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children per Standard of Care (POP02) study team has been engaged in a multi-institution, multi-study collaboration with National Institutes of Health (NIH) called The Collaboration to Assess Risk and Identify LoNG-term outcomes for Children with COVID (CARING for Children with COVID). This collaboration ...
  • Geaux Team – Louisiana Site Remains Committed Amidst Challenges October 18, 2021
    Many clinical sites that are contributing to the enrollment of Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children per Standard of Care Study (POP02) are facing unique challenges presented by the COVID-19 Delta surge. However, Ochsner Baptist Medical Center (OBMC), in New Orleans, Louisiana has faced more unique challenges than most. In addition ...
  • POP02 Continues to Enroll Rapidly and Meet Study Milestones October 1, 2021
    This year, the Pediatric Trial Network (PTN) has now enrolled over 600 pediatric participants into its Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children per Standard of Care (POP02) Study, which includes SARS-CoV-2 positive participants. As of September 2021, there are more than 400 SARS-CoV-2 participants and over 100 participants with multisystem inflammatory ...
 
 

News icon

news